Accuray Incorporated · NASDAQ:ARAY
Accuray — Q2 FY2024 Earnings Presentation
15 slides from Accuray's earnings presentation, Jan 31, 2024
Slide 1: Q2'FY24 Earnings Call Supplemental Presentation
Q2’FY24 Earnings Call Supplemental Presentation January 31, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are
Slide 3: Delivering on Our Strategy
ACCURAY . C) Delivering on Our Strategy <q
Slide 4: Closing the Gaps to Cancer Care
Closing the Gaps to Cancer Care Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled H
Slide 5: Our Strategic Growth Plan: Key Pillars
Our Strategic Growth Plan: Key Pillars Guided by Our Vision: To expand the curative power of radiation therapy to improve as many lives as possible Grow revenue through innovation to advance care and expand access Operational excellence and efficiency Expand service revenue with installed base growt
Slide 6: Expanding Access to Breast Cancer Segment: VitalHold for the Radixact System
Expanding Access to Breast Cancer Segment: VitalHold™1 for the Radixact® System Accuray Solution Radixact® System + VitalHold™ provides unmatched treatment delivery versatility Received Shonin approval and launched VitalHold at JASTRO in Japan VitalHold now is cleared to sell in Japan, US and EU obt
Slide 7: Expanding Access to Global Value Segment: Accuray Helix Tomo C
Expanding Access to Global Value Segment Accuray Helix™ Tomo® C Locally Manufactured, China Solution Manufactured in Madison, Wisconsin Fueling Growth in China Type B Market Unique Features Designed for Workflow Efficiency
Slide 8: CyberKnife System Momentum
CyberKnife® System Momentum YOY new orders growth: Q2: +45%; 1H +38% Growing SRS/SBRT programs driven by clinical evidence (prostate, lung, brain) Driving trade-in, trade-up of aged installed base: 63% of Q2 TITU orders Key reference sites order 2nd system
Slide 9: Q2'FY24 and 1H'FY24 Financials
Q2’FY24 and 1H’FY24 Financials Strong financial performance KEY FINANCIAL METRICS Highlights Robust orders with book-to-bill ratio of 1.8 New product innovation stimulating order momentum EIMEA driving orders and revenue Installed base growth helping drive service revenue increase Provided Q3 FY24 r
Slide 10: Maintaining FY24 Guidance
Maintaining FY24 Guidance Communicated August 9, 2023 Takes into account expectations regarding uncertainty and impact from macro environmental climate, FX and inflation Revenue Adjusted EBITDA1 $447.6M $23.9M FY24 Guidance Range FY23 Actual $ in millions % = YoY Growth $460M - $470M +3% - 5% $27M -
Slide 11: Thank you
ACCURAY Thank you
Slide 12: GAAP to Adjusted EBITDA Q2 FY'24 and Q2 FY'23 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended December 31, 2023 Three Months Ended December 31, 2022 $ $ $ $ (9,621) 1,546 2,314 2,713 878 2,008 (1,874) 1,151 3,126 2,642 1,049 8,49
Slide 13: GAAP to Adjusted EBITDA 1H FY'24 and 1H FY'23 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Six Months Ended December 31, 2023 Six Months Ended December 31, 2022 $ $ $ $ (12,590) 2,797 4,706 5,341 2,810 8,512 (7,323) 2,327 6,042 4,898 1,390 10,39
Slide 14: GAAP to Adjusted EBITDA Q3 FY'24 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (1,000) 1,300 2,300 2,600 800 6,000 2,000 1,300 2,300 2,600 800 9,000 GAAP to Adjusted EBITDA Q3 FY’24 – Forward Looking Guidance Actual R
Slide 15: GAAP to Adjusted EBITDA FY'24 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (6,400) 5,000 9,200 10,000 3,800 27,000 (3,400) 5,000 9,200 10,000 3,800 30,000 ERP and ERP related expenditures 2,800 2,800 GAAP to Adjus